Scarica l'app Stockscreener
26.61
2.59%
-0.834
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Precedente Chiudi:
$27.44
Aprire:
$26.71
Volume 24 ore:
422.78K
Relative Volume:
0.24
Capitalizzazione di mercato:
$2.71B
Reddito:
$352.57M
Utile/perdita netta:
$-143.01M
Rapporto P/E:
-14.70
EPS:
-1.81
Flusso di cassa netto:
$-153.40M
1 W Prestazione:
-7.57%
1M Prestazione:
+8.09%
6M Prestazione:
+28.02%
1 anno Prestazione:
+2.37%
Intervallo 1D:
$25.96
$27.12
Intervallo di 1 settimana:
$25.96
$28.96
Portata 52W:
$13.53
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
Nome
Beam Therapeutics Inc
Settore
Industria
Telefono
857-327-8775
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
26.66 | 2.79B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.07 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
769.77 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
729.48 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.27 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.56 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-10-09 | Iniziato | Jefferies | Buy |
| 2025-03-28 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-10 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-08 | Downgrade | Jefferies | Buy → Hold |
| 2023-10-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Iniziato | Citigroup | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-01-05 | Iniziato | Guggenheim | Buy |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-09-24 | Ripresa | Stifel | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Redburn | Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Iniziato | Wells Fargo | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-08-05 | Iniziato | William Blair | Outperform |
| 2020-03-02 | Iniziato | Barclays | Overweight |
| 2020-03-02 | Iniziato | JP Morgan | Overweight |
| 2020-03-02 | Iniziato | Jefferies | Buy |
| 2020-03-02 | Iniziato | Wedbush | Outperform |
Mostra tutto
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
HC Wainwright Predicts Weaker Earnings for Beam Therapeutics - MarketBeat
JPMorgan Chase & Co. Trims Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
ARK Investment Boosts Stake in Beam Therapeutics - National Today
Amova Asset Management Americas Inc. Buys 103,939 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Earnings Call Highlights PKU Pivot - TipRanks
What is HC Wainwright's Forecast for BEAM Q1 Earnings? - MarketBeat
Mintz Advises Sixth Street On $500 Million Strategic Financing Facility With Beam Therapeutics - Mondaq
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) - ADVFN Ltd
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com UK
Contrarius Group Holdings Ltd Buys Shares of 1,533,269 Beam Therapeutics Inc. $BEAM - MarketBeat
BEAM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vanguard Group Inc. Sells 455,440 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
BEAM SEC FilingsBeam Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
BEAM.O PE Ratio & Valuation, Is BEAM.O Overvalued - Intellectia AI
RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here’s Why - Yahoo Finance
Beam Therapeutics (NASDAQ:BEAM) Raised to Hold at Wall Street Zen - MarketBeat
BEAM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Should You Buy Beam Therapeutics Inc (BEAM) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Assessing Beam Therapeutics (BEAM) Valuation After Q4 Earnings Surprise Credit Facility And PKU Program Launch - simplywall.st
Beam Therapeutics: Great Potential, But Patience Is Needed (NASDAQ:BEAM) - Seeking Alpha
Beam Therapeutics reveals new program for PKU - BioWorld MedTech
Bernstein SocGen cuts Beam Therapeutics stock price target on valuation By Investing.com - Investing.com Canada
Bernstein SocGen cuts Beam Therapeutics stock price target on valuation - Investing.com
Beam Therapeutics Clarifies Growth Path With PKU Program And New Financing - Yahoo Finance
Beam Therapeutics (BEAM) Quarterly Profit Surprises Loss Narrative With US$244.3 Million Net Income - simplywall.st
Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.3%Time to Sell? - MarketBeat
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street - WilmerHale
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y - Finviz
Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $26.00 - MarketBeat
BEAM Shares See Target Price Boost by RBC Capital | BEAM Stock N - GuruFocus
Beam Therapeutics Stock Surges 14% on Strategic Financing: How the $500M Agreement Secures a $156 Target - TIKR.com
Beam Therapeutics Opens with 7.83% Gain, Outperforming S&P 500's 0.69% Rise - Markets Mojo
Beam Therapeutics Hits Day High with 17.04% Surge in Stock Price - Markets Mojo
Wedbush Raises BEAM Price Target to $65, Maintains Outperform Ra - GuruFocus
Beam Therapeutics (NASDAQ:BEAM) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Beam Therapeutics (BEAM) stock edges up premarket after 14% jump on results, $500 million facility - Bez Kabli
RBC Capital Adjusts Beam Therapeutics Price Target to $26 From $22, Maintains Sector PerformSpeculative Risk Rating - marketscreener.com
Beam Therapeutics Inc. (NASDAQ:BEAM) Q4 2025 Earnings Call Transcript - Insider Monkey
Mintz Advises Sixth Street on $500 Million Strategic Financing Facility with Beam Therapeutics - Mintz
Decoding Beam Therapeutics Inc (BEAM): A Strategic SWOT Insight - GuruFocus
Beam Therapeutics Inc. (BEAM) Stock Analysis: Exploring a 72.96% Potential Upside in the Biotech Innovator - DirectorsTalk Interviews
Beam Therapeutics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Earnings Call Summary | Beam Therapeutics(BEAM.US) Q4 2025 Earnings Conference - 富途牛牛
[144] Beam Therapeutics Inc. SEC Filing - Stock Titan
BofA raises Beam Therapeutics stock price target on pipeline progress By Investing.com - Investing.com Australia
Beam Therapeutics Inc (BEAM) Q4 2025 Earnings Call Highlights: Strategic Financing and ... By GuruFocus - Investing.com Canada
Beam Therapeutics Inc (BEAM) Q4 2025 Earnings Call Highlights: S - GuruFocus
What's Going On With Beam Therapeutics Stock?Beam Therapeutics (NASDAQ:BEAM) - Benzinga
BofA raises Beam Therapeutics stock price target on pipeline progress - Investing.com
Beam Therapeutics Shares Rise After Swinging to Q4 Adjusted Earnings - marketscreener.com
Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Beam Therapeutics Inc Azioni (BEAM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ciaramella Giuseppe | President |
Feb 24 '26 |
Sale |
32.00 |
35,000 |
1,120,042 |
190,216 |
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):